© 2013 Autism Speaks Inc. Autism Speaks and Autism Speaks It’s Time To Listen & Design are registered trademarks owned by Autism Speaks Inc. All rights reserved.

Preclinical  Au,sm  Consor,um    for  Therapeu,cs  (PACT)  Your  partner  to  enable  discovery  of  new  medica6ons  for  ASD  

 Jacqueline  

Crawley,  Ph.D.  

Carrie  Jones,  Ph.D.  

Mustafa  Sahin,  M.D.,  Ph.D.  

Daniel  Smith,  Ph.D.  

To  partner  with  PACT,  contact:  Daniel.Smith@Au,smSpeaks.org  

What: a preclinical target validation platform for novel ASD medicines

Why: to reduce risk & increase successful

investment in ASD drug discovery

© 2013 Autism Speaks Inc. Autism Speaks and Autism Speaks It’s Time To Listen & Design are registered trademarks owned by Autism Speaks Inc. All rights reserved.

PACT  Advantages  ü  Built  for  industry  partnerships  (Contact:  Daniel.Smith@Au,smSpeaks.org)  

ü  Exper,se:  PACT  PIs  and  Advisors  have  strong  experDse  in:  Au6sm  medical  and  behavioral  care,  Au6sm  therapeu6cs  and  drug  discovery  and  development,  Au6sm  gene6cs  and  gene6c  animal  models,  Neuropsychopharmacology.  

ü  CuFng-­‐edge:  PACT  offers  the  latest  geneDc  rodent  models  of  ASD,  including  mice  and  rats  with  mutaDons  in  risk  genes  for  auDsm.  

ü  Reliable:    The  PACT  plaGorm  has  been  well-­‐replicated  in  independent  cohorts  of  each  rodent  model.  

ü  Transla,onal:  EEG  signatures,  seizure  analysis,  social  and  repeDDve  behaviors,  circadian  rhythms,  cogniDve,  sensory,  anxiety-­‐related,  and  other  assays  relevant  to  the  diagnosDc  and  associated  symptoms  of  auDsm.